South African pharma mogul Stephen Saad’s Aspen stake sinks under $360 million
Aspen Pharmacare CEO Stephen Saad loses $32 million in 13 days as stock slumps; his stake now worth under $360 million amid JSE sell-off.
Aspen Pharmacare
South African pharma tycoon Stephen Saad’s Aspen stake falls below $400 million
Stephen Saad’s stake slips below $400 million as Aspen shares fall 5.2% dragging market cap under $3 billion.
South African tycoon Stephen Saad's Aspen opens regional headquarters in Saudi Arabia
Aspen’s investment comes amid a broader push to localize manufacturing, enhance drug supply chains, and develop regional talent.
Stephen Saad’s Aspen stake drops $21 million in value
This mirrors wider investor caution amid challenges facing the global pharmaceutical sector and instability in emerging markets.
Stephen Saad raises Aspen stake by $5.6 million amid stock slump
Stephen Saad invests $5.6 million more in Aspen amid its biggest stock slump in two decades, signaling confidence in the company’s long-term outlook.
Stephen Saad loses $130 million as Aspen shares fall amid contract dispute
This follows a $148.7 million contract dispute tied to mRNA technology.
Stephen Saad’s Aspen faces $148.7 million contract dispute
Aspen shares dive 30% amid $148.7 million mRNA tech dispute, stoking investor fears over financial stability.
Gus Attridge gains over $18 million as Aspen shares rebound
This follows a strong recovery in Aspen's share price on the Johannesburg Stock Exchange (JSE).
Stephen Saad’s stake in Aspen slips below $450 million
South African pharma tycoon Stephen Saad’s stake in Aspen Pharmacare drops to $434.35 million, losing $62.85 million in 15 days.
South African tycoon Gus Attridge loses $15.73 Million as Aspen stake sinks
Attridge, co-founder and group chief advisor of Aspen Pharmacare, holds a 4.3-percent stake in the company.
Stephen Saad’s wealth takes a hit as Aspen Pharmacare stock plunges, erasing $41 million
This downturn follows a $44 million gain in January, which had lifted his stake to R10.26 billion ($550.1 million).
Stephen Saad leads Africa’s largest drugmaker to $1.2 billion in half-year revenue
The growth was fueled by the successful integration of acquired products in Latin America.
Africa’s largest asset manager buys additional stake worth $67 million in Stephen Saad’s Aspen Pharmacare
With this latest transaction, PIC’s stake in Aspen is now worth nearly a billion dollars—R15.2 billion ($824.24 million).
South African pharma tycoon Stephen Saad’s Aspen stake rises above $550 million
With the recent rise in Aspen's stock price, the value of his holdings has crossed $550 million, marking a recovery after a challenging 2024.
South African businessman Gus Attridge sees Aspen stake drop by $9.3 million
This corresponds to a 5.24 percent drop in Aspen’s stock price on the Johannesburg Stock Exchange (JSE) in 9 days.
Stephen Saad’s Aspen stake drops $99.7 million in 2024
This downturn is driven by a sustained decline in the market value of his holdings in Aspen Pharmacare, Africa's largest pharmaceutical company.